Novo Nordisk A/S: stock overview

NVONYSEHealthcare · Pharmaceutical Preparations

Price

$40.70

November 17, 2026Market cap $181B

What Ploutos Investor adds for Novo Nordisk A/S

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 7 fiscal years, from 2019
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Novo Nordisk A/S had revenue of $48.6B in the fiscal year to December 31, 2025 and net income of $16.1B, a net margin of 33.1%. Revenue grew by 19.5% a year on average over the last 5 years. At $40.70 the shares trade at a P/E of 11.2, against a median of 35.5 over the last 5 fiscal years. It has net debt of $17.8B. It pays a dividend yielding 4.52%.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 17, 2026.

Its SEC filings
Market cap
$181B
4.44B shares
P/E
11.2
Today11.2
Median35.5
Revenue, fiscal year
$48.6B
+19.5% a year over 5 years
Net margin
33.1%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

+15.4% a year over 2 years

  • 202520-F
    Revenue$48.6B
  • 202420-F
    Revenue$40.3B
  • 202320-F
    Revenue$34.5B

Fiscal years in figures

NVO's revenue, profit, cash flow and dividend with each year-end price, from 2019 to 2022, 4 more fiscal years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 5 fiscal years.

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 3-year median: $382B
$181B
Enterprise value 
$199B
P/E 3-year median: 27.4
11.2
EV / EBIT 
9.9
EV / Revenue 
4.1
P/B 3-year median: 19.2
5.9
FCF yield 3-year median: 2.7%
5.1%
Earnings yield 3-year median: 3.7%
8.9%

Profitability

Gross margin 
81.0%
Operating margin 
41.3%
Net margin 3-year median: 34.8%
33.1%
ROIC 
31.0%
ROIC, 5-year average 
46.9%
ROE, fiscal year 
52.8%

Growth

Revenue, yearly change 
+6.4%
EPS, yearly change 
+1.8%
FCF, yearly change 
-20.1%
Revenue, average a year 
+19.5%
EPS, average a year 
+20.7%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$4.2B
Total debt 
$21.9B
Net debt 
$17.8B
Net debt / EBITDA 
0.8x
Interest cover 
–
Current ratio 
–

Balance sheet of December 31, 2025.

Returns to shareholders

Dividend yield 3-year median: 1.8%
4.52%
Buybacks 
0.12%
Total returned 
4.64%
Shares, yearly change 
+0.1%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
NOVO NORDISK A S
Exchange
NYSE
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
DKK
Shares
4.44B

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Novo Nordisk A/S's filings show?

These are Novo Nordisk A/S's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about NVO

Didn't find what you were looking for?

Ask us
What is NVO's market cap?

Novo Nordisk A/S's market cap is $181B, at a price of $40.70 on November 17, 2026 and 4.44B shares.

What is NVO's P/E?

NVO's P/E is 11.2, on earnings per share of $3.62 in the fiscal year to December 31, 2025. The median over the last 5 fiscal years was 35.5.

How much revenue does NVO have?

Novo Nordisk A/S had revenue of $48.6B in the fiscal year to December 31, 2025. Over the last 5 years it changed by +19.5% a year on average.

Does NVO pay a dividend?

Yes. Novo Nordisk A/S paid $1.84 per share over the last 12 months, a yield of 4.52% at today's price. All the figures are in the Dividend section.

Where do the figures come from?

From Novo Nordisk A/S's SEC filings (its annual report on 20-F) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.